Noncoding RNAs: From Disease to Targeted Therapeutics

joint with Protein-RNA Interactions: Scale, Mechanisms, Structure and Function of Coding and Noncoding RNPs

Organizer(s): Kevin V. Morris, Archa Fox and Paloma Hoban Giangrande

Sponsored by Cell Research, Ionis Pharmaceuticals, Inc. Merck & Co., Inc. and Moderna Therapeutics

Summary of Meeting:

It has become apparent over the last decade that small and long noncoding RNAs play a major role in the regulation of gene expression and disease. While much emphasis has been centered on the role of noncoding RNAs in human disease, a gap remains in utilizing this knowledge to develop target specific approaches to disrupting noncoding RNA pathways for therapeutic gain. This meeting will for the first time bring together an interdisciplinary group of basic and applied noncoding RNA scientists in an effort to translate our current understanding of noncoding RNA biology into meaningful therapeutics for many of those diseases afflicting society. To accomplish this goal, the meeting will aim to: (1) Introduce the broad genome-wide basic fabric of noncoding RNA regulation and form and function in the cell; (2) Focus on direct RNA/chromatin/DNA or RNA/protein interactions with candidate disease-relevant model systems; and (3) Highlight synthetic biological approaches to developing RNA or oligonucleotide mimics to target and/or disrupt particular disease-relevant noncoding RNA pathways. The goal of this meeting is to bring together basic and applied scientists working on noncoding RNAs in an effort to not only better understand the role noncoding RNAs play in the regulation of disease-relevant genes but also the emerging ability to utilize this knowledge to develop targeted therapeutics, an eventuality that heralds a new frontier in drug development and therapeutics.

Scholarship Deadline: October 5 2016

Discounted Abstract Deadline: October 5 2016

Abstract Deadline: November 2 2016

Discounted Registration Deadline: December 6 2016

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Elpidera LLC, a Moderna Venture

Integrated DNA Technologies

We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA213553-01
Funding for this conference was made possible (in part) by 1R13CA213553-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations